Bio-Rad Laboratories (BIO)

$305.49 +11.25 (3.82%)
Market Cap 8.27B
Revenue (ttm) 2.57B
Net Income (ttm) -1.84B
EPS (ttm) N/A
PE Ratio 29.25
Forward PE 30.57
Profit Margin -71.86%
Debt to Equity Ratio 0.17
Volume 241,500
Avg Vol 262,556
Day's Range N/A - N/A
Shares Out 27.06M
Stochastic %K 99%
Beta 0.97
Analysts Sell
Price Target $331.40

Company Profile

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, q...

Industry: Medical Devices
Sector: Healthcare
Phone: 510 724 7000
Fax: 510 741 5817
Address:
1000 Alfred Nobel Drive, Hercules, United States
highnihilism
highnihilism Oct. 1 at 11:50 AM
$SKM SK Telecom Trades: 5 | Total $: 1.8 K | 1.26 × 90-Day Avg $: 1.5 K | Call $: 540 | Put $: 1.3 K | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $SRI Stoneridge Trades: 1 | Total $: 540 | 0.13 × 90-Day Avg $: 4.3 K | Call $: 540 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $BOAT Sonichasers Global Shipping ETF Trades: 2 | Total $: 540 | 0.39 × 90-Day Avg $: 1.4 K | Call $: 540 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $BIO Bio-Rad Laboratories Trades: 2 | Total $: 537 | 0.01 × 90-Day Avg $: 54.8 K | Call $: 537 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 30 at 1:54 PM
$BIO Going up on news
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 30 at 8:29 AM
$BIO Very high affinity binding (Kₙ < 1 pM) to the TSLP receptor, allowing Verekitug to outcompete TSLP even in presence of preformed receptor complexes. In a Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP), a 100 mg dose every 12 weeks met both primary and secondary endpoints at Week 24, with generally favorable tolerability. erekitug’s receptor-targeting approach (versus ligand targeting) may deliver stronger, more durable inhibition, potentially achieving better efficacy or dosing convenience.
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 30 at 8:28 AM
$BIO Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress By Upstream Bio | September 30, 2025, 4:15 AM
0 · Reply
SuperGreenToday
SuperGreenToday Sep. 30 at 1:42 AM
$BIO Share Price: $270.12 Contract Selected: Mar 20, 2026 $260 Calls Buy Zone: $25.84 – $31.92 Target Zone: $47.92 – $58.57 Potential Upside: 75% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 26 at 8:32 AM
Enter: $BIO OCT 17 2025 $280 CALLS Buy in Price: $11.20 - $12.00 Take Profit: $16.69 Stop Bleeding: $9.86 ROI Potential: 49% Exit Within: 166 Minutes https://moneygroup.us/alerts
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 23 at 12:51 PM
$BIO Current Stock Price: $283.00 Contracts to trade: $280 BIO Oct 17 2025 Call Entry: $10.08 Exit: $13.91 ROI: 38% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 22 at 3:19 PM
$BIO Current Stock Price: $283.83 Contracts to trade: $280 BIO Oct 17 2025 Call Entry: $7.00 Exit: $10.47 ROI: 50% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 19 at 6:22 PM
Enter: $BIO OCT 17 2025 $290 CALLS Buy in Price: $6.35 - $11.00 Take Profit: $14.86 Stop Bleeding: $5.59 ROI Potential: 134% Exit Within: 343 Minutes https://moneygroup.us/alerts
0 · Reply
MorenitaScorp
MorenitaScorp Sep. 16 at 11:40 PM
$BIO ⌚️
0 · Reply
Latest News on BIO
Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.

Sep 4, 2025, 5:19 PM EDT - 4 weeks ago

Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.

Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 4, 2025, 5:07 PM EDT - 4 weeks ago

Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Bio-Rad's Management to Participate in Upcoming Investor Conferences

Aug 25, 2025, 9:00 AM EDT - 5 weeks ago

Bio-Rad's Management to Participate in Upcoming Investor Conferences

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

Aug 7, 2025, 7:30 AM EDT - 2 months ago

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Aug 1, 2025, 11:30 AM EDT - 2 months ago

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025

Aug 1, 2025, 9:00 AM EDT - 2 months ago

Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025

Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:55 PM EDT - 2 months ago

Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript

Bio-Rad Reports Second-Quarter 2025 Financial Results

Jul 31, 2025, 4:15 PM EDT - 2 months ago

Bio-Rad Reports Second-Quarter 2025 Financial Results

Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

Jul 28, 2025, 4:15 PM EDT - 2 months ago

Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025

Jul 17, 2025, 4:15 PM EDT - 2 months ago

Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025

Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

Jul 7, 2025, 9:00 AM EDT - 3 months ago

Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

May 29, 2025, 4:30 PM EDT - 4 months ago

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025, 4:30 PM EDT - 5 months ago

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

May 1, 2025, 10:35 PM EDT - 5 months ago

Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

Bio-Rad Reports First-Quarter 2025 Financial Results

May 1, 2025, 4:15 PM EDT - 5 months ago

Bio-Rad Reports First-Quarter 2025 Financial Results

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 11:45 PM EST - 8 months ago

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Feb 13, 2025, 4:20 PM EST - 8 months ago

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Feb 13, 2025, 4:15 PM EST - 8 months ago

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Jan 27, 2025, 5:00 PM EST - 8 months ago

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Jan 8, 2025, 8:15 AM EST - 9 months ago

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

LH

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Jan 2, 2025, 4:30 PM EST - 9 months ago

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Bio-Rad's Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Nov 21, 2024, 9:00 AM EST - 11 months ago

Bio-Rad's Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 8:22 PM EDT - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Oct 30, 2024, 6:09 PM EDT - 1 year ago

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Bio-Rad Reports Third-Quarter 2024 Financial Results

Oct 30, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad Reports Third-Quarter 2024 Financial Results

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Oct 14, 2024, 5:30 PM EDT - 1 year ago

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Sep 6, 2024, 6:43 PM EDT - 1 year ago

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

ADNT CHCT CMP CNH DBI DDD DELL

Bio-Rad's Management to Participate in Fireside Chat During Wells Fargo's 2024 Healthcare Conference

Aug 22, 2024, 4:30 PM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During Wells Fargo's 2024 Healthcare Conference

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:47 PM EDT - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Aug 1, 2024, 5:56 PM EDT - 1 year ago

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Bio-Rad Reports Second-Quarter 2024 Financial Results

Aug 1, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad Reports Second-Quarter 2024 Financial Results

Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024

Jul 17, 2024, 4:30 PM EDT - 1 year ago

Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024

Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group

May 30, 2024, 9:00 AM EDT - 1 year ago

Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group

Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference

May 23, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference

Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:16 PM EDT - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript

Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip

May 7, 2024, 6:11 PM EDT - 1 year ago

Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip

Bio-Rad Reports First-Quarter 2024 Financial Results

May 7, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad Reports First-Quarter 2024 Financial Results

Bio-Rad's Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference

May 1, 2024, 9:00 AM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference

Bio-Rad Announces Life Science Group Management Changes

Apr 26, 2024, 8:30 AM EDT - 1 year ago

Bio-Rad Announces Life Science Group Management Changes

Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Apr 18, 2024, 9:00 AM EDT - 1 year ago

Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Bio-Rad's Chief Operating Officer Andrew Last to Retire

Apr 10, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad's Chief Operating Officer Andrew Last to Retire

Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer

Mar 20, 2024, 8:30 AM EDT - 1 year ago

Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer

Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day

Feb 22, 2024, 4:30 PM EST - 1 year ago

Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day

Bio-Rad Laboratories, Inc. (BIO) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 6:54 PM EST - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q4 2023 Earnings Call Transcript

Bio Rad Labs rises after posting upbeat fourth-quarter profit

Feb 15, 2024, 6:51 PM EST - 1 year ago

Bio Rad Labs rises after posting upbeat fourth-quarter profit

Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results

Feb 15, 2024, 4:15 PM EST - 1 year ago

Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results

Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024

Jan 24, 2024, 5:00 PM EST - 1 year ago

Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 42nd Annual Healthcare Conference

Jan 2, 2024, 4:15 PM EST - 1 year ago

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 42nd Annual Healthcare Conference

highnihilism
highnihilism Oct. 1 at 11:50 AM
$SKM SK Telecom Trades: 5 | Total $: 1.8 K | 1.26 × 90-Day Avg $: 1.5 K | Call $: 540 | Put $: 1.3 K | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $SRI Stoneridge Trades: 1 | Total $: 540 | 0.13 × 90-Day Avg $: 4.3 K | Call $: 540 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $BOAT Sonichasers Global Shipping ETF Trades: 2 | Total $: 540 | 0.39 × 90-Day Avg $: 1.4 K | Call $: 540 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $BIO Bio-Rad Laboratories Trades: 2 | Total $: 537 | 0.01 × 90-Day Avg $: 54.8 K | Call $: 537 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 30 at 1:54 PM
$BIO Going up on news
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 30 at 8:29 AM
$BIO Very high affinity binding (Kₙ < 1 pM) to the TSLP receptor, allowing Verekitug to outcompete TSLP even in presence of preformed receptor complexes. In a Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP), a 100 mg dose every 12 weeks met both primary and secondary endpoints at Week 24, with generally favorable tolerability. erekitug’s receptor-targeting approach (versus ligand targeting) may deliver stronger, more durable inhibition, potentially achieving better efficacy or dosing convenience.
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 30 at 8:28 AM
$BIO Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress By Upstream Bio | September 30, 2025, 4:15 AM
0 · Reply
SuperGreenToday
SuperGreenToday Sep. 30 at 1:42 AM
$BIO Share Price: $270.12 Contract Selected: Mar 20, 2026 $260 Calls Buy Zone: $25.84 – $31.92 Target Zone: $47.92 – $58.57 Potential Upside: 75% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 26 at 8:32 AM
Enter: $BIO OCT 17 2025 $280 CALLS Buy in Price: $11.20 - $12.00 Take Profit: $16.69 Stop Bleeding: $9.86 ROI Potential: 49% Exit Within: 166 Minutes https://moneygroup.us/alerts
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 23 at 12:51 PM
$BIO Current Stock Price: $283.00 Contracts to trade: $280 BIO Oct 17 2025 Call Entry: $10.08 Exit: $13.91 ROI: 38% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 22 at 3:19 PM
$BIO Current Stock Price: $283.83 Contracts to trade: $280 BIO Oct 17 2025 Call Entry: $7.00 Exit: $10.47 ROI: 50% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 19 at 6:22 PM
Enter: $BIO OCT 17 2025 $290 CALLS Buy in Price: $6.35 - $11.00 Take Profit: $14.86 Stop Bleeding: $5.59 ROI Potential: 134% Exit Within: 343 Minutes https://moneygroup.us/alerts
0 · Reply
MorenitaScorp
MorenitaScorp Sep. 16 at 11:40 PM
$BIO ⌚️
0 · Reply
MorenitaScorp
MorenitaScorp Sep. 3 at 10:18 PM
$BIO ⌚️
0 · Reply
MorenitaScorp
MorenitaScorp Sep. 2 at 12:35 PM
$BIO 🔬
0 · Reply
EV_Rebel
EV_Rebel Aug. 23 at 7:28 AM
$BIO/B Bio-Rad Laboratories Class B non-voting shares with same economic interest
0 · Reply
5GFlipper
5GFlipper Aug. 23 at 7:28 AM
$BIO Bio-Rad Laboratories Inc has complex ownership structure and life sciences exposure
0 · Reply
Spicy_Trade
Spicy_Trade Aug. 3 at 4:29 PM
SpicyTrade Bio-Rad Laboratories, Inc. ( $BIO ) daily stock analysis https://youtu.be/85FMTC2bkmI?si=jWwDQ7Qy6YBrvpiJ
0 · Reply
BioTechHealthX
BioTechHealthX Aug. 1 at 6:38 PM
$BIO Bio-Rad Labs rallied after crushing earnings expectations. Learn how process chromatography and ddPCR growth could power even bigger gains. https://biotechhealthx.com/biotech-news/bio-rad-labs-bio-smashes-earnings-estimates-is-the-stock-ready-to-explode/
0 · Reply
topstockalerts
topstockalerts Aug. 1 at 3:46 PM
$BIO there she goes…🏦🏦
0 · Reply
JarvisFlow
JarvisFlow Aug. 1 at 3:23 PM
RBC Capital has adjusted their stance on Bio-Rad Laboratories ( $BIO ), setting the rating to Outperform with a target price of 387 → 409.
0 · Reply
topstockalerts
topstockalerts Aug. 1 at 2:13 PM
Top Gainers PT2 $LXEH $TILE $ANTE $FDMT $BIO
0 · Reply
d_risk
d_risk Aug. 1 at 1:50 PM
$BIO - Bio-Rad Laboratories Inc. Class A Common Stock - 10Q - Updated Risk Factors BIO’s 2025 10-Q reveals heightened risks from complex global compliance, supply chain and innovation delays, geopolitical and economic instability, cyber and IT disruptions, currency volatility, regulatory shifts, organizational changes, tax reforms, ESG pressures, rising debt, and intensified litigation exposure. #Biotechnology #GeopoliticalInstability #Cybersecurity #SupplyChainRisk #GlobalCompliance 🟢 Added 🟠 Removed https://d-risk.ai/BIO/10-Q/2025-07-31
0 · Reply
topstockalerts
topstockalerts Aug. 1 at 12:11 PM
$BIO where's she going once market opens? ..🍾🍾 ..
0 · Reply
jbess22
jbess22 Aug. 1 at 1:05 AM
$PSTV $BIO $UNH $BGLC
0 · Reply